Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher

Rallybio Corporation RLYB shares are trading higher after the company announced a collaboration with Johnson & Johnson JNJ to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is a rare immune…#rallybiocorporation #johnsonjohnsonjnj #fnait #rallybio #johnsonjohnson #johnsonjohnsons #phase2
Source: Reuters: Health - Category: Consumer Health News Source Type: news